In breast cancer xenografts, a single intravenous eribulin administration increased the Hoechst-based tumor-perfusion endpoint, with different dose responses in MX-1 and MDA-MB-231 models. Capecitabine reduced tumor growth without increasing that endpoint. These results support a vascular effect beyond tumor shrinkage in these models, without directly establishing improved delivery of another drug. [3]
Vascular and antitumor responses varied across a separate ten-model xenograft survey. Eribulin increased microvessel density significantly in six models, with a model-level association between vascular and antitumor responses (R² = 0.54). H460 showed no antitumor effect, limiting generalization across tumor models. [4]
Tumor perfusion after a single eribulin administration
Animal study · Female nude mice bearing human MX-1 or MDA-MB-231 breast cancer xenografts [3]
Hoechst-positive tumor area increased after eribulin in a model- and dose-dependent manner. Capecitabine inhibited MDA-MB-231 tumor growth without increasing the perfusion endpoint, arguing against tumor shrinkage alone explaining the finding.
- MX-1 eribulin dose response
- Model: Female nude mice, MX-1 xenograft
- Route: Intravenous
- Frequency: Single administration on day 1
- Treatment course: Perfusion assessed day 6
- Reported limits: Vehicle formulation not specified in selected main text.
- MDA-MB-231 eribulin dose response
- Model: Female nude mice, MDA-MB-231 xenograft
- Route: Intravenous
- Frequency: Single administration on day 1
- Treatment course: Perfusion assessed day 6
- Reported limits: Vehicle formulation not specified in selected main text.
- MDA-MB-231 capecitabine comparator
- Model: Female nude mice, MDA-MB-231 xenograft
- Route: Oral
- Frequency: Daily
- Reported limits: Precise daily course and vehicle formulation not specified in selected main-text perfusion description.
Methods and source locations
Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin
Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.
Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
Tumor Hoechst 33342-positive area on day 6: Figure 2c–d; paper uses Dunnett multiple comparison test unless otherwise noted; Figure 2 marks p < 0.05, p < 0.01 or p < 0.001 versus vehicle — Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
MDA-MB-231 tumor growth and perfused area under comparator treatment: Tumor volume-derived weight on day 8 and Hoechst-positive area; comparator monotherapy, not a combination — Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
MX-1 eribulin dose response · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
MDA-MB-231 eribulin dose response · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
MDA-MB-231 capecitabine comparator · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption
Tumor response and vascular density across ten xenograft models
Animal study · Female CAnN.Cg-Foxn1nu/CrlCrlj nude mice with H460, A549, H441, H1993, HCT116, Calu-6, HCC827, H1975, A427 or LOX xenografts [4]
A cross-model survey found significant microvessel-density increases in six of ten models and an association with antitumor effects. H460 showed no antitumor effect. The correlation does not establish a universal vascular mechanism or causation.
Conditions shared by the study groups
- Route
- Tail-vein injection
- Frequency
- One injection on day 0
- Treatment course
- MVD on day 7; model-specific longitudinal tumor follow-up
- Eribulin ten-model survey
- Model: Female CAnN.Cg-Foxn1nu/CrlCrlj nude mice with H460, A549, H441, H1993, HCT116, Calu-6, HCC827, H1975, A427 or LOX xenografts
- Reported limits: Vehicle formulation not specified in selected main text. n = 6/group for tumor response and n = 3 for MVD, not one common n.
Methods and source locations
Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin
Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.
Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption
Significant microvessel-density enhancement across ten xenograft models: CD31 immunohistochemistry; Figure 1b/caption and first Results subsection — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption
Association of MVD enhancement with antitumor effects: Figure 1d; MVD ratio versus ΔT/C; association across models, not a causal intervention — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption
Antitumor effect in H460 xenografts: Figure 1a and first Results paragraph; relative tumor volume time courses — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption
Eribulin ten-model survey · Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption